GLP-1 Trial Subgroup Analysis: When a Promising Chart Misleads

A GLP-1 trial subgroup analysis checks whether the treatment effect looks different in slices of the trial, such as women versus men, older versus younger people, or people with and without diabetes. These charts are useful for spotting questions, but they mislead easily: subgroups are smaller, many slices get tested at once, and chance alone produces "differences" that aren't real.

You'll usually see subgroups in a chart called a forest plot. Here's how to read one without getting fooled, starting with the most famous subgroup in medical history.

What happened with the star-sign subgroup?

In the 1980s, a huge trial called ISIS-2 tested aspirin after heart attacks. Overall, aspirin clearly helped, with a P value below 0.00001.

The investigators then did something mischievous. Because every patient's birth date was recorded, they split the results by astrological sign. In two of the twelve signs, Gemini and Libra, aspirin appeared to have a slightly harmful, non-significant effect.

Nobody thinks aspirin knows your star sign. The point, as one of the trial's leaders later wrote, is that splitting a trial into enough slices will throw up odd-looking results by chance alone. His paper's title says it all: subgroup analyses are "fun to look at, but don't believe them!"

Why do subgroup results go wrong so often?

Three reasons, in plain words:

1. Smaller groups, shakier numbers. A subgroup is a fraction of the trial, so its estimate comes with a wider margin of error. (See confidence intervals explained.)
2. Lots of tests. If a drug works the same in everyone and you test 20 subgroups, each at the usual 5% threshold, you'd expect about one "significant" difference just by luck. The chance of at least one false alarm is roughly 64%.
3. Hindsight stories. After seeing a surprising result, it's easy to invent a plausible reason. Plausible isn't proof.

How do you read a forest plot?

A forest plot lists subgroups down the left side. For each one there's a square (the estimated effect) and a horizontal line (the confidence interval). A vertical line marks "no effect."

Quick reading guide:

• Squares to the left of the line usually mean the drug did better than placebo (for outcomes like heart attacks, check the axis label).
• Lines crossing the "no effect" line mean that subgroup's result is uncertain on its own.
• Overlapping lines between subgroups usually mean there's no clear evidence they differ.
• The column labeled "P for interaction" is the one that actually tests whether the effect differs between subgroups.

That last point is the big one. The 2025 update of the CONSORT trial-reporting guideline puts it plainly: the question is not whether a subgroup shows a statistically significant result, but whether the subgroup effects are significantly different from each other.

A real GLP-1 example: does it work better in women?

A 2026 meta-analysis pooled cardiovascular outcome trials of newer diabetes and weight medicines, including GLP-1 receptor agonists. In people with type 2 diabetes, GLP-1 drugs reduced major heart events in men (hazard ratio 0.89) and in women (0.83).

A tempting headline: "GLP-1 drugs protect women's hearts more!" But the authors found that formal interaction tests were not statistically significant. In plain words: benefits were broadly similar in both sexes, and the slightly bigger number in women could be chance.

The same paper found something arguably more important: women made up only about one-third of participants in these trials. That's a gap in who gets studied, which we cover in who gets left out of GLP-1 trials.

Spot the trick

1. "The drug worked in people under 65 (significant) but not in people over 65 (not significant). So older people shouldn't bother."

Show answer

This is the most common subgroup mistake. "Significant in one group, not in the other" is not evidence of a difference. The older subgroup might just be smaller. Look for the interaction test. If it isn't significant, the best estimate for older people is usually the overall trial result.

2. "A new analysis finds the drug works especially well in people with [specific trait]."

Show answer

Ask: was this subgroup planned before results were known (prespecified), or found afterward (post hoc)? CONSORT 2025 notes that post hoc subgroup findings are especially likely not to be confirmed by later studies.

3. "Subgroup charts are useless, ignore them."

Show answer

Too far the other way. Subgroups can show that results are consistent across groups, which is reassuring, and they can point to real questions worth a dedicated trial. Just treat a surprising subgroup result as a lead, not a verdict.

Scoring: 3 out of 3? You've earned the right to say "what was the P for interaction?" at dinner parties. Use it wisely.

What makes a subgroup finding more believable?

Researchers use a checklist like this one:

More believable	Less believable
Planned before the results were known	Found after looking at the data
One of a few subgroups tested	One of dozens
Significant interaction test	Only "significant here, not there"
Direction predicted in advance	Explanation invented afterward
Seen again in other trials	Seen once
A sensible biological reason	Star signs

What should you do with a subgroup headline?

Enjoy it as a question. If it touches on your situation (your age, sex, diabetes status), it's fair to ask your prescriber whether the overall trial results apply to you. That's a better question than "should I change my treatment because of one chart?", and the answer to that one is no, not without talking to them first.

For the rest of your headline toolkit, run the five-minute headline routine and check the relative vs absolute risk math too.

Common questions

What is a subgroup analysis in a clinical trial?

It's a look at whether the treatment effect differs in parts of the trial population, such as by sex, age, weight or diabetes status. Results are less precise than the overall trial result.

What does "P for interaction" mean?

It's the result of a statistical test that checks whether the treatment effect really differs between subgroups. A non-significant interaction means the trial didn't find good evidence of a difference.

Do GLP-1 medicines work differently in men and women?

In the 2026 pooled analysis of cardiovascular outcome trials, heart benefits were broadly similar in both sexes, and formal interaction tests were not significant. Women were underrepresented, so more data would help.

Are prespecified subgroups always reliable?

They're more credible than post hoc ones, but still limited by smaller numbers and multiple testing. Consistency across trials makes them stronger.